Danaher acquires Masimo for $9.9bn
Change
Danaher agreed to buy Masimo in a $9.9 billion cash deal that values Masimo at $180 per share and will operate Masimo as a standalone business unit within Danaher's diagnostics division.
Why it matters
The transaction brings a leading pulse oximetry supplier under Danaher's operational and distribution systems, reducing the number of independent vendors for hospital and acute-care purchasers. Competitor device makers will face greater difficulty matching Danaher's combined scale and global sales channels.
Implications
- • Hospital procurement departments must reassess sourcing, contract terms, and price comparisons for pulse oximetry equipment in light of a consolidated supplier under Danaher.
- • Pulse oximeter manufacturers' commercial and distribution teams must revise go-to-market and pricing strategies to compete with Danaher's integrated diagnostics platform.
Unlock the decision layer.
See what the change means — implications, exposure, timing — and ask AI about any brief instantly.
- Implications: What actually changes downstream.
- Who is affected: Which teams or operators are exposed.
- What to watch: Deadlines, triggers, and next moves.
- Real-time alerts: Know the moment a change is published.
- Ask AI: Clarify any brief instantly, in context.
14-day free trial. Full access. No credit card required.
Start free trial
Source
Topics
Mergers & Acquisitions Pharma & Biotech Healthcare Systems Medical Research